Drug Trial Radar · NCT00721825
Study of NeuroAid In Enhancing Recovery After Stroke
Last checked: Nov 19, 2026Latest source record: Jul 24, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jan 2008
Primary completion
Jul 2008
Study completion Jul 2008
Sponsor
- Lead sponsor
- Moleac Pte Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 24, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TIERS is a phase II to generate detailed preliminary data on the efficacy of NeuroAid in post-stroke recovery, and to assess the utility of the rehabilitation outcome measure instruments used.
Conditions
- Stroke
- Cerebral Infarction
Interventions
NeuroaidDrug
Neuroaid capsules, 4 capsules, three times per day, during one month
Neuroaid matched PlaceboDrug
Neuroaid matched placebo 4 capsules three times per day during one month
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fugl-Meyer assessmentTime frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tan Tock Seng Rehabilitation department
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.